Sanofi Q4 Preview: CEO Hudson’s Planned Revamp Key Focus
Investors Seek More Details From Sanofi’s Top Exec On Growth Strategy
Sanofi’s Q4 update will highlight planned strategic changes and Dupixent’s key growth role, amid a strong rebound in quarterly US flu vaccine sales.
You may also be interested in...
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.